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CASE REPORT
Sustained complete response of advanced 
hepatocellular carcinoma with metronomic 
capecitabine: a report of three cases
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Abstract 
Background: Hepatocellular carcinoma (HCC) is one of the most frequent causes of cancer-related death. Sorafenib, 
a multitarget angiogenesis inhibitor, is an approved frontline treatment for advanced HCC in Western countries, 
although a complete response (CR) to treatment is infrequently reported. Capecitabine, an oral fluoropyrimidine, has 
been shown to be effect in both treatment-naïve patients and those previously treated with sorafenib. To date, how-
ever, only one case of sustained CR to metronomic capecitabine has been reported.
Case presentation: We describe three cases of advanced HCC treated with metronomic capecitabine where a CR 
was obtained. In the first case, capecitabine was administered as first line therapy; in the second case, capecitabine 
was used after intolerance to sorafenib; while in the third case, capecitabine was administered after sorafenib failure.
Conclusion: Capecitabine is a potentially important treatment option for patients with advanced HCC and may even 
represent a cure in certain cases.
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Background
Hepatocellular carcinoma (HCC) is a major challenge for 
oncologists, being the fifth most common cancer in men 
and the seventh in women, representing the third most 
frequent cause of cancer death worldwide [1]. Treatment 
strategies for HCC depend on both tumour stage and 
liver disease status.
In patients with advanced HCC, or where surgical or 
locoregional treatment is contraindicated because of 
underlying cirrhosis or patient characteristics, medical 
therapy becomes the only strategy [2]. Sorafenib, a multi-
kinase inhibitor, was the first molecular targeted therapy 
to demonstrate a survival benefit [3], and the only glob-
ally approved frontline treatment for advanced HCC. 
The efficacy of sorafenib has been demonstrated in two 
randomized, double-blinded, placebo-controlled phase 
III clinical trials: the Sorafenib HCC Assessment Rand-
omized Protocol (SHARP) [3] and the Asia-Pacific [4] tri-
als. Sorafenib is considered moderately effective in HCC 
treatment, with a less than 3-month increase in overall 
survival (OS) in comparison with placebo [3]. Cases of 
complete response (CR) to sorafenib have been reported 
in the literature [5], but no data on the duration of the CR 
are available.
Capecitabine is an oral fluoropyrimidine carbamate 
that acts as a 5-fluorouracil (5-FU) pro-drug to mimic the 
continuous infusion of 5-FU. It is globally approved for 
the treatments of colon, gastric, and breast cancer.
Capecitabine administration according to a standard 
(or reduced standard) schedule has been evaluated in the 
postoperative adjuvant setting after curative HCC resec-
tion [6], in advanced disease [7], and in recurrent HCC 
after liver transplantation [8]. In a small randomized 
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controlled trial among patients with HCC, 30 controls 
treated with best supportive care (BSC) were compared 
with 30 subjects who received 2  weeks of capecitabine 
at 1000 mg/m2, twice a day, followed by 1 week without 
treatment for a total of 4–6 cycles [6]. The data showed 
that adjuvant therapy with capecitabine was well toler-
ated, postponed and reduced the risk of HCC recurrence, 
and was likely to improve postoperative survival.
In a single-centre phase II, open-label trial, 52 patients 
with advanced HCC who had not received previous sys-
temic treatment were randomly assigned to receive either 
sorafenib (at a dose of 400  mg twice daily) or capecit-
abine to a modified standard schedule (1000 mg/m2 twice 
daily on days 1–14) [7]. Median OS was 7.05 months in 
the sorafenib group and 5.07 months in the capecitabine 
group. Thus, capecitabine at the modified dosing sched-
ule was found to be inferior to sorafenib with respect to 
OS [7]. However, when capecitabine was administered 
according to a metronomic schedule, varying results 
were reported [9, 10].
Metronomic therapy is defined as the continuous 
administration of a lower dose of cytotoxic drug, with-
out treatment pauses [11]. While standard chemo-
therapy exerts an antiproliferative effect, metronomic 
chemotherapy functions to inhibit angiogenesis by 
directly disrupting endothelial cell proliferation, up-
regulating antiangiogenic factors such as thrombospon-
din-1 (TSP-1) and angiostatin, and down-regulating of 
angiogenic factors such as vascular endothelial growth 
factor (VEGF), basic fibroblast growth factor (b-FGF), 
and hypoxia-inducible factor-1 (HIF-1) [12]. Metronomic 
chemotherapy also inhibits vascular development by 
reducing the number and viability of circulating endothe-
lial progenitor cells from bone marrow [13]. In addi-
tion, metronomic chemotherapy stimulates the immune 
response by reducing regulatory T cells and promoting 
dendritic cell maturation [14, 15]. Low-dose regimens 
of chemotherapy can also induce senescence in tumours 
through an antiproliferative response [16]. The use of 
metronomic treatment is becoming more frequent for 
the treatment of various cancers, owing to its antiangio-
genic properties and tolerability. However, the effects of 
metronomic chemotherapy appear to vary according to 
solid tumour type.
Metronomic chemotherapy has been evaluated only 
to a limited extent for the treatment of advanced HCC. 
Hsu et al. [17] conducted a phase II study to evaluate the 
efficacy and safety sorafenib (400 mg twice daily) in com-
bination with metronomic tegafur/uracil (UFT) (125 mg/
m2 based on tegafur twice daily) in 53 patients with HCC 
and a Child–Pugh class A score. Median progression-
free survival was 3.7  months, and median survival was 
7.4  months. The use of metronomic chemotherapy and 
sorafenib was shown to augment antitumor efficacy with-
out a high incidence of severe side effects.
Metronomic capecitabine for advanced HCC, in first 
line treatment, has been evaluated in a phase II study, and 
was shown to be well tolerated and associated with an 
OS of 14.47 months, further emphasized by a propensity 
analysis comparing treated subjects with matched con-
trols [9]. Sustained CR to capecitabine was also reported 
[18]. In the present case report, we describe three cases 
of sustained CR following treatment with metronomic 
capecitabine in patients with advanced HCC. Informed 
consent to the treatment was obtained from the patients.
Case presentation
Case 1
An 84-year old man with chronic hepatitis C and liver 
cirrhosis was referred to our outpatient clinic for the 
evaluation of HCC, previously treated with transarterial 
chemoembolization (TACE) and radiofrequency abla-
tion (RFA). Following disease relapse, a wedge resec-
tion of two nodules in hepatic segments VI and VII was 
performed in December 2008. Histological examination 
confirmed HCC grade III (Edmondson scoring), with 
necrosis and microscopic vascular thrombosis.
In September 2009, magnetic resonance imaging 
(MRI) showed millimetric disease relapse in hepatic seg-
ments V, II, III, and I, and a 21 × 9 mm adenopathy at the 
hepatic hilum (Fig.  1a, b). A new resection was sched-
uled but was not carried out following the detection by 
intra-operative ultrasound (US) of a right portal branch 
neoplastic thrombosis. In December 2009, serum alpha-
fetoprotein (AFP) was 1504  ng/mL. In January 2010, as 
a consequence of disease metastasis, systemic treatment 
with metronomic capecitabine (500 mg twice daily) was 
continuously administered according to a previously 
described protocol [6]. The therapy was well tolerated. 
After 1 month, serum AFP decreased to 643 ng/mL, and 
3 months later, had drastically decreased to 7 ng/mL. At 
the same time, a marked reduction in liver lesion size was 
observed by MRI, evaluated as a partial response accord-
ing to Modified Response Evaluation Criteria in Solid 
Tumors (mRECIST) [19]. In August 2010, computer 
tomography (CT) scanning showed a single hypodense 
lesion of 13 mm in hepatic segment II without any other 
liver lesions, and that enlarged abdominal lymph nodes 
were stable and neoplastic thrombosis was not detected. 
Given the presence of a single lesion, the possibility of 
residual disease ablation was explored using hepatic con-
trast-enhanced ultrasound. Two suspicious lesions for 
HCC were detected in hepatic segments II and III, with-
out a typical contrastographic appearance. The lesions 
were submitted to needle biopsy, and histological analysis 
identified a nodule of low-grade dysplasia in segment II 
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and micro and macronodular cirrhosis with light activ-
ity in segment III. The patient underwent metronomic 
capecitabine until July 2013 when, considering the sus-
tained CR, treatment was discontinued and the patient 
entered a follow-up program. The final MRI (February 
2017, Fig. 1c, d) confirmed the CR. To date, the patient is 
alive and in good health.
Case 2
A 66-year old man had multiple liver lesions involving 
approximately 70% of the right liver, multiple nodules in 
the left lobe, and a right portal thrombosis in the setting 
of non-alcoholic steatohepatitis (CT scan in August 2012, 
Fig.  2a, b). Positron emission tomography (PET) with 
2-(fluorine-18)-fluoro-2-deoxy-d-glucose (FDG-PET) 
identified bone metastases in the proximal portion of 
the right femur, in the right ischial tuberosity, in the left 
acetabulum, in the left scapula, and in the third left costal 
arch. Moreover, a PET with (11)C-choline confirmed the 
hepatic and skeletal lesions and identified other metasta-
ses in the pelvic bones, rachis, and ribs. In October 2012, 
serum AFP was 1909  ng/mL. Considering the typical 
contrastographic pattern of the liver lesion by CT scan-
ning and the elevated AFP level, a diagnosis of HCC was 
made according to European Association for the Study of 
the Liver (EASL) guidelines [20].
In December 2012, the patient started systemic treat-
ment with sorafenib 800  mg/bid. Ten days later, the 
treatment was discontinued because of G3 skin tox-
icity (Stevens–Johnson syndrome). In January 2013, 
the patient started metronomic capecitabine (500  mg 
twice daily, continuous administration), which was 
well-tolerated. In March 2013, a new CT scan showed 
a reduction in the number and size of the liver lesions 
Fig. 1 Lesions in case 1. Gd-EOB-DTPA-enhanced MR images showing, at baseline acquisition, hepatobiliary phase 4 millimetric lesions: a 10 mm 
hepatocellular carcinoma (HCC) nodule in segment II (a), a 14 mm HCC nodule in segment III (b), and a millimetric lesion at segments V and I. 
Gd-EOB-DTPA-enhanced MR follow-up after 89 months since starting systemic treatment with metronomic capecitabine shows a stable complete 
response, with the absence of both HCC nodules (c, d)
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with significant intralesional necrotic areas. Subse-
quent FDG-PET scanning (April 2013) showed the 
complete absence of pathological areas and, in paral-
lel, AFP level had fallen to 3.3  ng/mL. In July 2013, a 
needle biopsy of the principal hepatic lesion evidenced 
fibrous connective tissue with histiocytic inflammation 
without tumour cells. An abdominal US scan (Janu-
ary 2014) revealed the presence of a single hypoechoic 
lesion of 1.4 × 1.3  cm. In December 2014, CT scan-
ning showed a further size reduction of the hypodense 
hepatic lesion without vascular components, and it was 
therefore decided to discontinue treatment in the same 
month. CT and US images, supported by histological 
patterns, showed a necrotic lesion with gradual resolu-
tion (Fig. 2c, d). In the most recent US scan (September 
2017), no hepatic lesion was detected and serum AFP 
was 3.6  ng/mL. The patient is currently alive and in 
excellent health.
Case 3
A 70-year-old man with hepatitis C virus cirrhosis was 
diagnosed with binodular HCC in Jul 2006 and treated 
with RFA and percutaneous ethanol injection (PEI). 
From March 2008 to March 2015, the patient experi-
enced multiple tumour recurrences, which were man-
aged using locoregional techniques (RFA, PEI, and one 
course of TACE). The patient came to our attention in 
October 2015 following HCC progression in the VIII 
segment associated with an invasion of the inferior vena 
cava and neoplastic pulmonary embolization. Serum 
AFP was 18,622 ng/mL. Systemic therapy with sorafenib 
was started at dosage of 400  mg/die, given the patient’s 
poor clinical condition, and increased to 600 mg/die after 
10 days. The patient started experiencing severe fatigue, 
diarrhoea, and dizziness, which prompted a reduction 
in dosage to 400  mg/die in November 2015. In Febru-
ary 2016, following radiological progression (tumoural 
Fig. 2 Lesions in case 2: axial CT images showing a large (10 cm) heterogeneous hypervascular hepatocellular carcinoma of segment VII in the 
arterial phase at baseline (a), with unequivocal wash-out in the venous phase (b); 32 months after starting systemic treatment with metronomic 
capecitabine, CT images show a complete response with the absence of viable tumour burden in the arterial phase (c), and only a 2 cm hypodense 
“scar” better identified in the venous phase (d)
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invasion of the right and median hepatic veins and 
enlargement of the neoplastic thrombus in the inferior 
cava vein) and a sharp increase in serum AFP (47,137 ng/
mL), the patient was switched to capecitabine therapy 
(500  mg twice daily, continuous administration). CT 
scanning performed every 3 months showed the progres-
sive reduction of pulmonary metastases, recanalization 
of the median hepatic vein, and progressive improvement 
in inferior cava vein invasion. Moreover, the tumour 
mass showed a complete devascularisation (Fig.  3a, b). 
Serum AFP levels decreased to 4583 ng/mL in May 2016, 
5.5  ng/mL in September 2016, 2.5  ng/mL in November 
2016, and 1.5 ng/mL in October 2017.
At the time of writing, the patient is in good clinical 
condition and continues to receive capecitabine treat-
ment (500 mg bid), complaining only of modest fatigue.
Discussion
The efficacy of metronomic capecitabine in advanced 
HCC has been evaluated both as frontline and post-
sorafenib treatment in retrospective analysis [10, 12] 
and in a phase II prospective trial [9]. In the first retro-
spective study, the outcome of 26 patients treated with 
metronomic capecitabine after sorafenib failure was 
reported, with a median OS of 8  months [10]. Another 
retrospective case–control study reported a median OS 
of 12  months in patients treated with capecitabine ver-
sus 9  months in patients who received only BSC [21]. 
Furthermore, a large multicentre retrospective analysis 
compared patients treated with metronomic capecitabine 
or BSC after sorafenib discontinuation and found that the 
median survival was approximately 10 months in patients 
treated with metronomic capecitabine and less than 
5 months in those receiving BSC. This benefit was con-
firmed in patients matched in a propensity analysis [22].
In 2013, our group published a phase II study on met-
ronomic capecitabine in patients with advanced HCC. 
Metronomic capecitabine (500  mg twice daily continu-
ously without breaks) was administered to 59 patients 
naïve to systemic therapy and 31 patients who were intol-
erant to sorafenib or following sorafenib failure. Median 
PFS and OS were 6.03 and 14.47  months, respectively, 
in the first-line group, and 3.24 and 9.77  months in the 
second-line group. Additionally, we recorded two cases 
of CR and one of partial response in sorafenib-naïve 
patients [9].
Fig. 3 Lesions in case 3: a pre-treatment CT scan (coronal image of the portal fase). The image shows vascular invasion of the right and medium 
hepatic veins and of the inferior cava vein. Two neoplastic embolisms are present in the left lung. b Following 18 months of treatment with 
metronomic capecitabine, vascular vein invasion was resolved and pulmonary embolisms had disappeared
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Other sustained (but incomplete) tumour responses 
have been observed in three cases of unresectable HCC 
treated with metronomic capecitabine [21, 23].
The difference between the absolute number of CR 
cases linked to sorafenib (51 cases of CR following a Pub-
Med search with the string “HCC OR hepatocellular car-
cinoma AND sorafenib AND complete AND response”) 
and to metronomic capecitabine is likely attributable to 
the limited use of metronomic capecitabine for HCC, in 
contrast with the sorafenib, the standard treatment. No 
data on the duration of sorafenib-related CR are available 
in the literature, reinforcing the rationale for exploring 
the efficacy of metronomic capecitabine
Moreover, important positive aspects of metronomic 
capecitabine treatment include its approximately 100-
fold lower cost than sorafenib, which is expected to 
further decrease in the near future following patent expi-
ration. Savings to national health systems associated with 
the use of metronomic capecitabine are therefore likely 
to be significant compared with sorafenib treatment.
To identify a biomarker predictive of treatment 
response and, subsequently, patients with advanced HCC 
who are more likely to benefit from therapy at an opti-
mal dose, it is necessary to explore the molecular deter-
minants of susceptibility to a given treatment strategy. 
Variation in lactate dehydrogenase serum level during 
sorafenib treatment is an example of such a biomarker 
[24].
Further studies are needed to understand the phenom-
enon of the long-term response to metronomic capecit-
abine observed in this case report. We can speculate 
that tumours showing a dramatic response to treatment 
are more likely to display a specific molecular pattern, 
preventing drug resistance. The use of next-generation 
sequencing techniques may help to clarify the determi-
nants of there markable responses observed in the cases 
reported here.
Conclusion
The outcomes of the three cases of CR described here 
suggest that metronomic capecitabine represents a viable 
treatment option in patients with HCC and may be highly 
effective in a subgroup of “super respondent” patients, 
with a rare but possible CR. CR linked to sorafenib and 
metronomic capecitabine suggests that a specific subset 
of HCC maybe particularly responsive to antiangiogenic 
treatment.
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